Q3 2024 Vaishali Pharma Ltd Earnings Call Transcript
Key Points
- Vaishali Pharma Ltd (NSE:VAISHALI) reported a strong financial performance in Q3 FY24 with total income rising to INR28.37 crores and an EBITDA margin of 12.05%.
- The company has a diversified product portfolio including APIs, formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products.
- Vaishali Pharma Ltd (NSE:VAISHALI) has a global presence with strategic partnerships in the Democratic Republic of Congo, Kenya, and Russia.
- The company introduced a new brand, Healthy, and launched innovative products like Healthy Biotin and Multivitamin Gummies.
- Vaishali Pharma Ltd (NSE:VAISHALI) aims to achieve INR500 crores in revenue with an EBITDA margin of 25% within the next five years.
- The company's margins have been historically volatile due to the varying performance of different business segments like APIs and formulations.
- Vaishali Pharma Ltd (NSE:VAISHALI) does not own its manufacturing units and relies on third-party manufacturing at 22 different sites, which may pose risks related to quality control and supply chain management.
- The company faces challenges in securing large international orders due to lengthy paperwork and regulatory requirements.
- The EBITDA margin for the nine months of FY24 was 16%, indicating room for improvement compared to the quarterly margin of 12%.
- Vaishali Pharma Ltd (NSE:VAISHALI) has a working capital cycle of 90 days, which may impact liquidity and operational efficiency.
Ladies and gentlemen, good day and welcome to Q3-FY24 result conference call of Vaishali Pharma Limited hosted by Kirin Advisors. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Vaishnavi Ambokar from Kirin Advisors. Thank you, and over to you, ma'am.
Thank you. On behalf of Kirin Advisors, I welcome you all to the conference call of Vaishali Pharma Limited. From the management side, we have Mr. Atul Vasani, Chairman and Managing Director; Mr. Dewansh Vasani, Executive Director; Mr. Ratnesh Singh, Chief Financial Officer.
Now, I hand over the call to Mr. Dewansh Vasani. Over to you, sir.
Good afternoon, and thank you for that warm welcome. I appreciate the opportunity to address the distinguished participants of this conference call. As we gather to discuss the performance of Vaishali Pharma Limited during the quarter
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
